Cadence OTC’s Morning After Pill will be available at convenience stores across the U.S.

Cadence OTC’s Morning After Capsule will likely be out there at comfort shops throughout the U.S.
Picture: Cadence OTC

The pharmaceutical firm Cadence OTC is making its emergency contraception remedy, the Morning After Capsule, out there at comfort shops throughout the U.S., the corporate stated Tuesday.

The Oakland, California-based Cadence OTC stated in a press release that it’s increasing entry to the tablet to serve markets the place it isn’t out there and to supply ladies residing in low-income or marginalized communities reasonably priced emergency contraception. Cadence OTC stated it is going to be the primary firm to supply emergency contraception over-the-counter at comfort shops.

Samantha Miller, Cadence OTC’s chief govt, stated “there are greater than 23 million ladies who reside in about 7,000 U.S. zip codes that do not need entry to over-the-counter emergency contraceptives.” The Morning After Capsule ought to needs to be as simple to seek out as condoms, she stated, partially as a result of there are greater than 150,000 comfort shops throughout the U.S. that keep open late.

The Morning After Capsule will likely be out there to individuals in smaller cities, together with so-called healthcare deserts and round school campuses, Miller stated. The expanded entry will assist stop unintended pregnancies, she added.

Cadence OTC’s transfer comes as pharmacy retail giants together with CVS and Walgreens have additionally expanded entry to ladies’s reproductive healthcare medicines. Earlier this month, the businesses stated they would begin selling mifepristone, a key abortion medication, in states the place abortion entry is authorized.

Walgreens and CVS stated simply days later that they would start selling Opill, an FDA-approved daily birth control pill.

Extra retail information

America’s retailers are dealing with a tangled mess

Best Buy and other retailers started 2024 by closing stores. They’re not done, analysts say


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *